TAE Life Sciences
- Company typePrivate
- Founded2017
- HeadquartersIrvine, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
TAE Life Sciences firmographics
Firmographics- Name
- TAE Life Sciences
- Legal name
- TAE Life Sciences US, LLC
- Website
- https://taelifesciences.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
TAE Life Sciences industry classification
Industry- Product category
- Radiation Oncology Systems
- NAICS
- Irradiation Apparatus Manufacturing (334517), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)
- akta.pro primary industry
- Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)
- akta.pro secondary industries
- Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE), Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology) (EUAKAIAD)
Keywords
Where TAE Life Sciences is headquartered
LocationHeadquarters
- HQ city
- Irvine
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
TAE Life Sciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Alphabeam BNCT System Sales: Sale of the Alphabeam accelerator-based neutron beam system to hospitals and cancer treatment centers for installation in clinical facilities. The system is designed for single or multi-room facility deployment.
- Boron-10 Drug Products: Proprietary boron-10 targeting drugs including BPA, TC220, and other novel compounds for use in BNCT treatment protocols. Partnership with Biddle Sawyer and Kinentia Biosciences for manufacturing.
- Distribution Partnerships: Revenue generated through exclusive distribution agreements with regional partners across multiple territories including Southeast Asia, Australia/New Zealand, Turkiye/Eastern Europe/Central Asia, and India.
- BPA (Steboronine) Commercialization: Exclusive commercial partnership with Stella Pharma for BPA development and commercialization in USA and European markets. Stella Pharma's BPA (Steboronine) is the world's first and only clinically approved boron drug for BNCT.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Contact sales for BNCT system and drug pricing |
Go-to-market motion4 records
Distribution channels6 records
Marketing channels7 records
TAE Life Sciences product offering
Product offeringCore offering
TAE Life Sciences develops Boron Neutron Capture Therapy (BNCT) technology, combining proprietary boron-10 targeted drugs with the Alphabeam™ accelerator-based neutron beam system for biologically targeted radiation therapy of cancer. The Alphabeam system is a compact tandem accelerator-based neutron source designed for hospital installation, while the boron-10 drug pipeline includes BPA, TC220, TC221, TC440, BTS, Antibody Boron Conjugates, and biodegradable nanoparticles targeting recurrent, invasive, and treatment-resistant cancers.
Product overview
TAE Life Sciences is developing a comprehensive BNCT (Boron Neutron Capture Therapy) platform consisting of the Alphabeam™ Neutron System (an accelerator-based neutron source for hospital deployment) combined with a pipeline of proprietary boron-10 drugs (including BPA, TC220, TC221, TC440, BTS, Antibody Boron Conjugates, and biodegradable nanoparticles). The Alphabeam system generates low-energy neutrons that interact with boron-10 drugs accumulated in tumor cells, causing selective destruction of cancer cells while sparing healthy tissue. The company is the only organization developing both the neutron beam system and targeted boron drugs internally for BNCT.
Differentiator
Problem solved
Functional benefit
Brands
- Alphabeam: The Alphabeam™ Neutron System is the company's accelerator-based neutron source designed for hospital installation, producing low-energy neutrons for BNCT treatment.
- BTS (Boronotyrosine)
- TC220
- TC440
- ABCs (Antibody Boron Conjugates)
Products and services
- Alphabeam Neutron System A compact tandem accelerator-based neutron source designed for hospital installation that generates low-energy neutrons for BNCT cancer treatment. Features 2.5 MeV proton energy, 10+ mA beam current capacity, lithium neutron target technology, negative ion electrostatic accelerator with no moving parts, and the smallest facility footprint for in-hospital use. Targets hospitals and cancer treatment centers implementing biologically targeted radiation therapy for recurrent, invasive, and treatment-resistant cancers.
- BPA (Boronophenylalanine) / Steboronine The first clinically approved boron-10 drug for BNCT, approved in Japan for head and neck cancer treatment. TAE Life Sciences is the exclusive commercial partner for Stella Pharma's BPA in the USA and Europe, working toward FDA and European approval under the product name Steboronine.
- TC220 (Boronated Amino Acid Analog) A novel boronated amino acid analog drug for BNCT targeting tumors expressing LAT-1, demonstrating superior boron delivery compared to BPA in preclinical studies. In preclinical development for GBM, breast, head and neck, and melanoma cancers. Manufactured by Biddle Sawyer with Kinentia Biosciences as exclusive manufacturer for US market.
- TC221 A next-generation boron drug candidate in preclinical development targeting lung, colon, and skin cancers.
- TC440 Boronated Dipeptide A boronated dipeptide compound demonstrating 2-3x higher boron delivery than BPA in xenograft models with 41% complete tumor remission versus 20% for BPA at same dose. Formulated in aqueous solutions at concentrations greater than 150mg/ml, with dual uptake via PEPT1 and LAT1 transporters.
- BTS (Boronotyrosine) / BTS(OMe) A patented borylated amino acid composition (US Patent No. 11,884,688 B2) comprising tyrosine derivatives BTS and BTS(OMe) for use in BNCT. Demonstrated 2-4x higher cellular uptake compared to BPA, 60% boron retention after 18 hours versus less than 20% for BPA, and improved tumor-to-blood ratio of 28:1 versus 6:1 for BPA.
- Antibody Boron Conjugates (ABCs) Next-generation boron drugs leveraging antibody-drug conjugate technology to improve tumor targeting and increase boron loading per cell. TAE Life Sciences has developed boron-enriched linkers (BELs) capable of carrying up to 400 boron atoms per antibody.
- Biodegradable Nanoparticles (BPMOs) Biodegradable mesoporous organosilica nanoparticles (BPMOs) developed in collaboration with Kyoto University for enhanced boron-10 delivery using the EPR effect for tumor targeting.
Quantifiable outcome
- 3x more destructive to cancer cells than standard radiotherapy
- +7 more outcomes
Companies that use TAE Life Sciences
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
TAE Life Sciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
Feature6 records
TAE Life Sciences partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered core and minor.
- CNAO (National Center for Oncological Hadrontherapy)coreResearch and clinical collaboration for implementation of BNCT system in Italy. CNAO is one of few facilities worldwide capable of delivering hadrontherapy using both protons and carbon ions, having treated over 6,000 patients. Expanding with BNCT including helium therapy, upright positioning systems, and BNCT system from TAE Life Science.
- Bozlu HoldingcoreExclusive distribution agreement for Turkiye, Eastern Europe, and Central Asia. Bozlu Holding is a diversified holding company headquartered in Istanbul with over 35 years of healthcare services expertise. Responsible for marketing, promoting, distributing, and selling the Alphabeam BNCT system and supporting deployment at initial clinical sites for regulatory approval in the region.
- Institut du Cancer de Montpellier (ICM)minorLaunch of AMBER Project to establish BNCT in France. Project aims to deploy TAE Life Sciences' Alphabeam BNCT system contingent on securing 45 million euros in funding to build dedicated facility.
- University of Wisconsin-MadisoncoreMOU signed to be the first US site to install the Alphabeam BNCT system and execute first US clinical trials. Focus on head and neck and brain cancers.
- Transmedic GroupcoreStrategic partnership to bring BNCT to Southeast Asia. Transmedic, a leading medical technology distributor headquartered in Singapore with over 40 years of local expertise, represents TAE Life Sciences in key Southeast Asian markets including Singapore, Malaysia, Hong Kong, and Thailand. Provides clinical, operational, and regulatory support to bring Alphabeam BNCT to regional hospitals.
- alphaXRTcoreDistribution agreement for Australia and New Zealand. alphaXRT, the leading independent supplier of radiation oncology equipment in Australia and New Zealand since 1990, will distribute Alphabeam BNCT system and novel boron drugs while also providing associated services. alphaXRT holds the regulatory certificate for BNCT in the region.
- Kyoto UniversitycorePreclinical research collaboration demonstrating breakthrough results in BNCT. Utilizing TAE Life Sciences' novel boron-10 drugs and Kyoto University Research Reactor (KURR) neutron source, research published in Journal of Medicinal Chemistry demonstrated abscopal effects and immune memory responses in BNCT treatment.
- Stella PharmacoreStrategic collaboration for BPA development, commercialization, and expansion in USA and European markets. Stella Pharma's BPA (Steboronine) is the world's first and only clinically approved boron drug for BNCT. Japan approved BNCT with Stella Pharma's BPA for head and neck cancers. TAE Life Sciences serves as exclusive commercial partner for Stella Pharma's BPA in USA and Europe. Clinical trials anticipated to begin in 2026.
- Radiosurgery GlobalminorNew distribution partner for India. RSG provides comprehensive support through network of consultants and advisors specializing in sales channels, project management, construction, digital and print marketing, investment advisory, engineering, service, and financing.
- Neuboron Medical Group / Neuboron Medtech Ltd.corePartnership for Chinese market where TAE Life Sciences' neutron beam system is a key component of Neuboron's NeuPex AB-BNCT System. System received performance acceptance and passed Class III registration inspection enabling human BNCT clinical trials to begin in China. First US company to achieve such recognition. Clinical trials commenced at Xiamen Humanity Hospital.
- Franciszek Lukasczyk Oncology Center (FLOC)minorPartnership with leading cancer center in Poland for new state-of-the-art BNCT facility. Construction projected to complete by 2025 with first clinical trials scheduled to commence in spring 2026.
- Biddle SawyercoreExclusive agreement with Biddle Sawyer as supplier of TC220, a novel boronated amino acid analog drug for BNCT. Biddle Sawyer enlisted Kinentia Biosciences as exclusive manufacturer of TC220 for US market to refine and streamline drug's manufacturing process in GMP facility.
- Xiamen Humanity HospitalcoreFirst accelerator-based BNCT clinical research center in China using TAE Life Sciences' Neutron Beam System as part of Neuboron Medical Group's NeuPex System. First cancer patient treatments completed.
- Aivita BiomedicalminorStrategic partnership to address unmet need in glioblastoma treatment, combining Aivita's stem cell applications with TAE Life Sciences' BNCT technology.
- HDX CorporationminorPartnership to bring TAE Life Sciences' targeted radiation therapy to South Korea for treatment of difficult-to-treat cancers such as brain, head and neck cancers and melanoma.
- CNAO (National Center of Oncological Hadrontherapy)coreAgreement to provide Alphabeam Neutron System for treatment of invasive, recurrent and difficult to treat cancers in Italy.
Scale indicators6 records
Recent moves7 records
Expansion highlights8 records
TAE Life Sciences competitors and assessment
Company assessmentDirect peers
- Neuboron Medical Group: China-based developer of the NeuPex AB-BNCT system that integrates TAE Life Sciences' neutron beam with Neuboron technology. Direct competitor in BNCT platform delivery and the closest peer in accelerator-based BNCT system development.
- Stella Pharma: Japanese pharmaceutical company that developed Steboronine (BPA), the world's first clinically approved boron drug for BNCT, approved in Japan for head and neck cancer. Direct peer in BNCT drug development and TAE's exclusive US/EU commercial partner.
- Sumitomo Heavy Industries: Japanese industrial conglomerate that developed reactor-based BNCT systems (used at Kyoto University and other Japanese centers). Direct competitor in BNCT hardware, particularly for hospital and research installations in Asia.
Broad incumbents
- Accuray: US-based radiation oncology systems company (CyberKnife, TomoTherapy) where TAE's CEO Robert Hill was previously SVP. Competes for the same hospital radiation oncology capital budgets but with established photon-based alternatives rather than BNCT.
- RaySearch Laboratories: Swedish developer of RayStation treatment planning software, which is integrated with TAE's Alphabeam system. Competes in radiation oncology treatment planning broadly and is a strategic partner/dependency for TAE's BNCT workflow.
- Varian Medical Systems (Siemens Healthineers): Global leader in radiation oncology hardware and software (TrueBeam, Ethos), now part of Siemens Healthineers. Competes for hospital oncology capex with mature conventional and adaptive radiotherapy platforms that BNCT must displace.
- Elekta: Swedish-Swiss manufacturer of linear accelerators and radiation therapy solutions including the Elekta Unity MR-LinAc. Competes in the same hospital radiation oncology purchasing decisions where TAE's BNCT system would be evaluated.
- Ion Beam Applications (IBA): Belgian leader in proton therapy systems (ProteusONE, ProteusPLUS) and a major competitor for the particle therapy capital budgets that BNCT systems must compete against in leading cancer centers.
- Hitachi (Particle Therapy): Japanese conglomerate with significant proton and particle therapy system business globally. Competes for hospital particle therapy installations and represents an alternative path for hospitals exploring advanced radiotherapy.
Emerging players
- Mevion Medical Systems: US-based developer of compact proton therapy systems (MEVION S250i). Competes with TAE in the niche of smaller-form-factor hospital-installable particle therapy, pursuing similar miniaturization thesis.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
TAE Life Sciences social profiles
Digital presenceTAE Life Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
TAE Life Sciences leadership team
Management profileNumber of profiles
Profiles8 records
TAE Life Sciences funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TAE Life Sciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TAE Life Sciences
What does TAE Life Sciences do?
TAE Life Sciences develops Boron Neutron Capture Therapy (BNCT) technology, combining proprietary boron-10 targeted drugs with the Alphabeam™ accelerator-based neutron beam system for biologically targeted radiation therapy of cancer. The Alphabeam system is a compact tandem accelerator-based neutron source designed for hospital installation, while the boron-10 drug pipeline includes BPA, TC220, TC221, TC440, BTS, Antibody Boron Conjugates, and biodegradable nanoparticles targeting recurrent, invasive, and treatment-resistant cancers.
Is TAE Life Sciences a public or private company?
TAE Life Sciences is a private company. It is classified as corporate owned and is currently operating.
When was TAE Life Sciences founded?
TAE Life Sciences was founded in 2017. It employs 51 to 100 people.
Where is TAE Life Sciences based?
TAE Life Sciences is headquartered in Irvine, United States, in the North America region.
How does TAE Life Sciences make money?
Four revenue lines are on record. Alphabeam BNCT System Sales are the primary driver. The others are boron-10 Drug Products, distribution Partnerships and BPA (Steboronine) Commercialization.
Who are TAE Life Sciences's main competitors?
Direct peers on record are Neuboron Medical Group, Stella Pharma and Sumitomo Heavy Industries. Broad incumbents are Accuray, RaySearch Laboratories, Varian Medical Systems (Siemens Healthineers), Elekta, Ion Beam Applications (IBA) and Hitachi (Particle Therapy). Mevion Medical Systems is listed as an emerging player.
Does TAE Life Sciences have an API?
No public API is recorded for TAE Life Sciences.
What industry is TAE Life Sciences in?
TAE Life Sciences's product category is Radiation Oncology Systems. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 334517 and its SIC code is 2836.